HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers.

AbstractPURPOSE:
Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors, associated with highly variable postoperative evolution. The scarcity of reliable PPGL prognostic markers continues to complicate patient management. In this study, we explored genome-wide DNA methylation patterns in the context of PPGL malignancy to identify novel prognostic markers.
EXPERIMENTAL DESIGN:
We retrospectively investigated DNA methylation patterns in PPGL with and without metastases using high-throughput DNA methylation profiling data (Illumina 27K) from two large, well-characterized discovery (n = 123; 24 metastatic) and primary validation (n = 154; 24 metastatic) series. Additional validation of candidate CpGs was performed by bisulfite pyrosequencing in a second independent set of 33 paraffin-embedded PPGLs (19 metastatic).
RESULTS:
Of the initial 86 candidate CpGs, we successfully replicated 52 (47 genes), associated with metastatic PPGL. Of these, 48 CpGs showed significant associations with time to progression even after correcting for SDHB genotype, suggesting their value as prognostic markers independent of genetic background. Hypermethylation of RDBP (negative elongation factor complex member E) in metastatic tumors was further validated by bisulfite pyrosequencing [Δβmetastatic-benign = 0.29, P = 0.003; HR, 1.4; 95% confidence interval (CI), 1.1-2.0; P = 0.018] and may alter transcriptional networks involving (RERG, GPX3, and PDZK1) apoptosis, invasion, and maintenance of DNA integrity.
CONCLUSIONS:
This is the first large-scale study of DNA methylation in metastatic PPGL that identifies and validates prognostic markers, which could be used for stratifying patients according to risk of developing metastasis. Of the three CpGs selected for further validation, one (RDBP) was clearly confirmed and could be used for stratifying patients according to the risk of developing metastases.
AuthorsAguirre A de Cubas, Esther Korpershoek, Lucia Inglada-Pérez, Eric Letouzé, Maria Currás-Freixes, Agustin F Fernández, Iñaki Comino-Méndez, Francesca Schiavi, Veronika Mancikova, Graeme Eisenhofer, Massimo Mannelli, Guiseppe Opocher, Henri Timmers, Felix Beuschlein, Ronald de Krijger, Alberto Cascon, Cristina Rodríguez-Antona, Mario F Fraga, Judith Favier, Anne-Paule Gimenez-Roqueplo, Mercedes Robledo
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 21 Issue 13 Pg. 3020-30 (Jul 01 2015) ISSN: 1557-3265 [Electronic] United States
PMID25825477 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright©2015 American Association for Cancer Research.
Chemical References
  • Biomarkers, Tumor
  • Transcription Factors
  • negative elongation factor
Topics
  • Adrenal Gland Neoplasms (diagnosis, genetics)
  • Adult
  • Biomarkers, Tumor (genetics)
  • CpG Islands
  • DNA Methylation
  • Female
  • Humans
  • Male
  • Paraganglioma (diagnosis, genetics)
  • Pheochromocytoma (diagnosis, genetics)
  • Sequence Analysis, DNA
  • Transcription Factors (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: